MDS - myelodysplastic syndrome
Myelodysplastic syndrome (MDS) refers to a heterogeneous group of closely related clonal hematopoietic disorders. Although clonal, MDS is considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia
Clasification of Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) can be classified as primary (no known exposure) or secondary as a complication of aggressive treatment of other cancers with exposure to radiation, alkylating agents, or topoisomerase II inhibitors and heavily pretreated patients with autologous bone marrow transplants.
Prevalence of MDS
Myelodysplastic syndrome is found worldwide and is similar in characteristics throughout the world. The actual incidence of myelodysplastic syndrome is unknown. Some estimates are on the order of 10,000 to 20,000 new cases each year in the United States alone. Some authors propose that the incidence in patients over 70 may be as high as 15 cases per 100,000 per year. The perception that the incidence of MDS is increasing may be due to improvements in recognition and criteria for the diagnosis. However the increasing number might be as well due to higher numbers in the aging population. International. The prevalence of myelodysplastic syndrome (MDS)is currently estimated at 35,000 to 55,000 cases in the USA. Statistics from 1999 show that in the US 13,000 new cases occur per year (approximately 1000 cases each year in children. 86% of myelodysplastic syndrome cases were diagnosed in individuals who were older than 60, and men had a significantly higher incidence rate than women (4.5 vs 2.7 per 100,000). Myelodysplastic syndrome diagnoses are rare in children Data for MDS based mainly in European numbers from Germany and Sweden were very similar to the USA numbers.
Prognosis for MDS
The prognosis for patients with Myelodysplastic syndrome depends on the following:
- Whether the myelodysplastic syndrome occurred after chemotherapy or radiation therapy for another disease.
- The number of blast cells in the bone marrow.
- Whether one or more types of blood cells are affected.
- Certain changes in the chromosomes.
Contact us regarding "MDS"
or call Tilo Stolzke at +49 451 400 83 01 directly.
Studies and publications myelodysplastic syndromes (MDS)
- Myelodysplastic Syndrome. The Leukemia & Lymphoma Society. White Plains, NY. 2001. p 24. Retrieved 05-12-2008.
- Kantarjian HM, O'Brien S, Shan J, et al. (2007). "Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome". Cancer 109 (2): 265-73.